Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Kilbourn

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Biochemical and Biophysical Research Communications|February 28, 1994
Cell-free hemoglobin reverses the endotoxin-mediated hyporesponsivity of rat aortic rings to alpha-adrenergic agentsR G Kilbourn, G Joly, B Cashon, et al.
Journal of Immunological Methods|July 16, 1987
Rapid, quantitative microassay for the monokine respiration inhibitory factorJ Klostergaard, R G Kilbourn, W A Foster, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 1, 1994
Cardiovascular effects of NG-methyl-L-arginine in chronically instrumented conscious dogsT Lechevalier, M F Doursout, J E Chelly, et al.
Cancer Research|May 15, 1991
Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cellsL M Li, R G Kilbourn, J Adams, et al.
The Cancer Journal From Scientific American|February 24, 2000
Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginineR G Kilbourn, G A Fonseca, L A Trissel, et al.
Critical Care Medicine|November 1, 1994
NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogsR G Kilbourn, D M Cromeens, F D Chelly, et al.
Journal of Critical Care|April 11, 2000
Effects of N-methyl-L-arginine on cardiac and regional blood flow in a dog endotoxin shock modelM F Doursout, R G Kilbourn, C J Hartley, et al.
The Journal of Urology|September 1, 1994
Phase II trial of low dose gamma-interferon in metastatic renal cell carcinomaJ A Ellerhorst, R G Kilbourn, R J Amato, et al.
Cancer Biotherapy|January 1, 1995
Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancerA Sella, B B Aggarwal, R G Kilbourn, et al.
Urologic Oncology|January 13, 2011
A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignanciesS M Tu, E D Robinson, R J Amato, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Biochemical and Biophysical Research Communications|February 28, 1994
Cell-free hemoglobin reverses the endotoxin-mediated hyporesponsivity of rat aortic rings to alpha-adrenergic agentsR G Kilbourn, G Joly, B Cashon, et al.
Journal of Immunological Methods|July 16, 1987
Rapid, quantitative microassay for the monokine respiration inhibitory factorJ Klostergaard, R G Kilbourn, W A Foster, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 1, 1994
Cardiovascular effects of NG-methyl-L-arginine in chronically instrumented conscious dogsT Lechevalier, M F Doursout, J E Chelly, et al.
Cancer Research|May 15, 1991
Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cellsL M Li, R G Kilbourn, J Adams, et al.
The Cancer Journal From Scientific American|February 24, 2000
Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginineR G Kilbourn, G A Fonseca, L A Trissel, et al.
Critical Care Medicine|November 1, 1994
NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogsR G Kilbourn, D M Cromeens, F D Chelly, et al.
Journal of Critical Care|April 11, 2000
Effects of N-methyl-L-arginine on cardiac and regional blood flow in a dog endotoxin shock modelM F Doursout, R G Kilbourn, C J Hartley, et al.
The Journal of Urology|September 1, 1994
Phase II trial of low dose gamma-interferon in metastatic renal cell carcinomaJ A Ellerhorst, R G Kilbourn, R J Amato, et al.
Cancer Biotherapy|January 1, 1995
Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancerA Sella, B B Aggarwal, R G Kilbourn, et al.
Urologic Oncology|January 13, 2011
A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignanciesS M Tu, E D Robinson, R J Amato, et al.
Pageof 5